Novel targeted therapies for autoimmunity

  • St Clair E
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


The emergence of new targeted therapies is rapidly improving the treatment of autoimmune disease. These drugs have been variably designed to deplete specific T and B cell subsets, interrupt receptor-ligand interactions, and inhibit the activity of inflammatory mediators relevant to immune function. Abatacept, a co-stimulatory blocker, and rituximab, a B cell depleting antibody, are among the approved therapies seeking new indications, while the newer therapies include Fc receptor-non-binding CD3-specific antibodies, IL-12/23 antibodies, an IL-6 receptor antagonist, a sphingosine-1-phosphate agonist, and small molecule inhibitors of intracellular protein kinases. Antigen-specific therapies are in their infancy, but the latest results administering glutamic acid dehydrogenase peptide to type 1 diabetics are promising. In the future, treatment strategies may increasingly explore the use of drug combinations acting at multiple sites of aberrant immunoregulation to achieve disease quiescence and immune tolerance.

Author-supplied keywords

  • Animals
  • Autoimmune Diseases
  • Cytokines
  • Humans
  • Immune Tolerance
  • Lymphocytes
  • Receptors: Immunologic

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • E William St Clair

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free